We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Debiopharm Group™ and Biocartis Enter Partnership to Enhance Personalized Medicine
News

Debiopharm Group™ and Biocartis Enter Partnership to Enhance Personalized Medicine

Debiopharm Group™ and Biocartis Enter Partnership to Enhance Personalized Medicine
News

Debiopharm Group™ and Biocartis Enter Partnership to Enhance Personalized Medicine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Debiopharm Group™ and Biocartis Enter Partnership to Enhance Personalized Medicine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, announced the signature of an investment agreement with Biocartis.

Financial details are not disclosed. The two partners will furthermore cooperate in the field of companion diagnostics linked to the therapies developed by Debiopharm (in the oncology and infectious diseases areas). Debiopharm’s contribution will be in the field of biomarkers, whilst Biocartis will use its recently created molecular diagnostic platform.

“Debiopharm understood a while ago the increasingly important role that companion diagnostics would play in the future” said Thierry Mauvernay, executive vice-president of Debiopharm Group, who added: ”we are extremely happy not only to have started a new financial partnership with a start-up company, but also to start a cooperation in an area that is extremely relevant and promising from the perspective of  personalized medicine and of the responsible use of financial resources. Biocartis, an early stage start-up company, has all the necessary strengths and management know-how to become a leading player in the field of in-vitro-diagnostics. Its potential combined with the disruptive technology it has created is perfectly in line with Debiopharm’s own efforts at the frontline of innovation in life-sciences at large”.
Advertisement